NCT01681940View on ClinicalTrials.gov

Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

August 31, 2012

Study Completion Date

September 30, 2013

Conditions
Alpha-Mannosidosis
Interventions
DRUG

Lamazym

ERT, i.v. infusions weekly

Trial Locations (4)

1090

Kinderneurologie Metabole Ziekten, UZ Brussel, Laarbeeklaan 101, Brussels

14004

Servicio de Pediatría, Hospital Materno Infantil, Reina Sofía, Avda Menéndez Pidal sn, Córdoba

DK-2100

Center for Metabolic Diseases, Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen

M13 9WL

Genetic Medicine, 6th floor, St Mary's Hospital, Oxford Road,, Manchester

All Listed Sponsors
collaborator

European Commission

OTHER

lead

Zymenex A/S

INDUSTRY

NCT01681940 - Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis | Biotech Hunter | Biotech Hunter